Lupin shares touch 52-week high as Q1 profit surges 77%
Lupin deals in branded and generic formulations, active pharmaceutical ingredients (APIs), and biosimilars.
lupin company
August 2024
November 2023
September 2023
August 2023
June 2023
May 2023
March 2023
January 2023
Lupin shares trade 3% higher; nears 52-week high after USFDA's approval
The drug will be manufactured at Lupin’s Pithampura plant in India, says the company.
Lupin shares hit 52-week high on strong Q2 results
The company's revenue from operations in the Q2 of FY24, stood at ₹5,038.6 crore, up 21.5% YoY as against ₹4,145.5 crore in the same period last year.
Lupin acquires five brands from Italy's Menarini to strengthen therapy portfolio
The brands are Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor), the company says.
Lupin shares hit 52-week high on plans to transfer two APIs, select R&D operations to LMSL
The share price of the company surged as much as 4.08% to hit a 52-week high of ₹1,174.00 in early session.
Lupin shares rise 2% on launching heart drug in Canada
The pharma major’s subsidiary has launched Propranolol LA capsules, 60 mg, 80 mg, 120 mg, and 160 mg, in Canada.
Lupin hits 52-week high on US FDA nod for respiratory drug
The scrip opened a gap-up at ₹834.95 on Wednesday against the closing price of the previous session at ₹829.65.
Lupin stock surges on robust sales in March quarter
In the March quarter, the company’s profit before tax stood at ₹235.9 crore as against the net loss of ₹517.9 crore in the same period last year.
Lupin shares dip 4% on US FDA observations for Pithampur unit
The U.S. drug regulator has issued Form 483 with ten observations for Lupin’s Pithampur unit-2 manufacturing facility.
Lupin launches asthma drug DIFIZMA; stock gains
The pharma major has launched a novel fixed-dose triple drug combination ‘DIFIZMA’ to treat inadequately controlled asthma.
